

ETHOS CAPITAL INVESTOR PRESENTATION

15 MARCH 2023



Performance review

Portfolio overview


Liquidity analysis

Outlook



EXECUTIVE SUMMARY


Six months ended 31 Dec 2022 headlines at a glance



*Based on aggregate attributable and earnings-based valuations ** R42 million used as partial repayment of EF VII facility.



ETHOS CAPITAL STRATEGY





TRADING COMPARABLES

MARKET BENCHMARKING OF FUND PERFORMANCE

Overview of the unlisted portfolio

JSE PERFORMANCE

Index	# companies	6 months	1 year	3 years		
Index		Absolute growth	Absolute growth	CAGR		
JSE All Share (excluding penny stocks)	237	7%	(4%)	3%		
Ethos Benchmark + excl. int. stocks, Naspers, mining, real estate)	170	2%	(6%)	(0.1%)		
EF VI	12	(4%)	1%	(3%)		
EMMFI	9	(3%)	(1%)	(2%)		
EF VII (excl. Brait)	2	19%	34%	31%	Ei	
EAIF I	4	3%	9%	17%	8. O	
Brait Ords (at NAVPS)	4	0.4%	3%	n/a		

Ethos Capital's **NAVPS increased by 1%, 7% and 7%** (CAGR) respectively over the past 6 months, 12 months and 3 years (based on Brait's NAVPS)


This compares with an ncrease in the **Ethos 3enchmark stocks of 2%, 6)% and 0%**

Ethos Capital average EV / EBITDA multiple increased to 8.2x due to the re-rating of Optasia post transaction

The Ethos Capital portfolio is valued at an attributable EV/EBITDA multiple of 8.2x compared to the attributable trading comparables of 13.0x (a 36% discount)

Over the 6-month period, trading comparables have increased from 12.7x to 12.8x (+3%) versus the attributable Ethos Capital multiple which increased by 6% (from 7.7x to 8.2x)


	Dec 21	Jun 22	growth %	Dec 22	growth %
Trading comparables	14.4x	12.7x	(12%)	12.8x	1%
Ethos Capital	7.5x	7.7x	+4%	8.2x	+6%
Discount	(48%)	(39%)		(36%)	



Fund returns adjusted for acquisitions during relevant periods

PORTFOLIO PERFORMANCE

- 1.3% increase in NAVPS for the 6-month period to 31 Dec 2022 from R10.66 to R10.80
 - 8% return on the unlisted portfolio largely driven by Optasia revaluation post the partial sale and growth in Gammatek, Synerlytic and Chibuku, offsetting negative returns from Autozone and Vertice
 - The listed portfolio value decreased due to declines of 17% and 18% respectively in the MTN ZF and Brait EB share prices



- 0.2% increase in NAVPS to R8.51 assuming Brait is valued at its 31 Dec 2022 share price
- Attributable maintainable EBITDA(2) decreased by 4% (largely Vertice and Autozone) with an attributable EV / EBITDA of 8.2x (largely Optasia and Crossfin)
- Attributable LTM revenue and EBITDA growth(2) of Top 5 unlisted portfolio of c.23% and 16%

(1) The movements from opening to closing balance have been adjusted for underlying transactions into / from Portfolio Companies; (2) Based on aggregate

At 30 June 2022

ytic

At 31 Dec 2022





PERFORMANCE REVIEW

. ETHOS CAPITAL LIQUIDITY

- Ethos Capital remains fully invested with Invested Capital of c.R2.6 billion
- R323 million of RMB facility drawn at 31 Dec 2022 (reduced to R250 million in Jan 23 with Optasia proceeds); R450 million committed and covenant levels reset
- Current net undrawn commitments total c.R131 million across the various Ethos Funds

- INVESTMENTS AND DISPOSALS

- R152 million invested in past year by Ethos Funds with Ethos Capital share of R61 million
- Gross proceeds of R214 million received following Optasia transaction, Crossfin, Gammatek and Brait EB coupon
- Optasia partial sale to new consortium at >20% premium to carrying value at 30 June 2022
- Retail Capital realised in Crossfin at 55% premium to pre-sale carrying value

- STRATEGIC OUTLOOK

- Current focus of Ethos Funds on portfolio optimisation and exits
- Ethos Capital Board remains focused on maximising value and return of capital to shareholders
- No new Fund commitments until Funds' realisation strategies and shareholder distributions have been demonstrated











ETHOS C A P I T A L

PORTFOLIO COMPANY PERFORMANCE OVERVIEW

Overview of Ethos key unlisted Portfolio Companies

- Strong operational performance has continued but FX losses impacting US\$ reported results
- 26% increase in LTM Revenue y-o-y, driven by advances growth and higher services penetration. LTM EBITDA growth negatively impacted by weaker FX rates in key geographies
 - Business development pipeline remains robust with growth opportunities from geographic and product diversification



- Good performance y-o-y with LTM revenue growth of 11% and EBITDA up 20%, benefitting from the upfront investment in people and value creation initiatives
- WearCheck is recovering after implementing price increases to combat input cost pressure
- The Particle Group has continued to deliver strong operational results; AMIS and CDN are both exceeding budget
- Echo SA continues to perform well; YTD EBITDA materially up on prior year due to strong revenue growth and stringent cost containment
- Revenue growth in SA driven by new customer wins and growth in the existing customer base
- International business continues to underperform due to long sales cycles and slow pipeline conversion; management team is exploring
 organic and inorganic options to return the sub-scale international operations to profitability



- The operating environment remains challenging however, elective surgeries have started to normalise
- Large, specialised businesses are performing well and above budget, driven by cardiology and cardiovascular
- A strategic review of smaller underperforming business units has resulted in the sale of a number sub-scale businesses



- Strong revenue growth but EBITDA growth rate has slowed; Adumo negatively affected by loadshedding and investment in marketing
- Crossgate is performing well and will benefit from the launch of a world-class personalised banking facility in Cape Town
 - Sybrin has been impacted by delays in the implementation of new projects in Africa



PORTFOLIO COMPANY PERFORMANCE OVERVIEW

Brait Portfolio Company overview










OVERVIEW OF PROGRESS ON BRAIT


Ethos participated in the Brait Rights Issue and was appointed as advisor to the Brait Board with a strategy of maximising / realising value from the portfolio within 5 years



TRACK RECORD OF REALISED RETURNS

ETHOS

Realised returns from exited Ethos Funds (in ZAR)



Value uplift represents the NAV increase at exit over NAV 1 year prior to exit * denotes a partial realisation for Ethos Capital (Optasia) or a capital raising event (Tyme Bank)



Performance review

Portfolio overview

Liquidity analysis

Outlook



ETHOS CAPITAL NAV ANALYSIS

Changes in NAV since June 2022


	Audite	d	С	hanges H1 20)22	Unaudit (Brait at N		Unaudi (Brait at shai	
	30 Jun 2022	le	Reval	Invested	Realised	31 Decen 2022		31 Decen 2022	
PORTFOLIO	3,209	99.5%	92	61	(172)	3,190	97.1%	2,602	96.4%
Brait (at NAV)	1,081	33.5%	3			1,084	33.0%	497	18.4%
Optasia	765	23.7%	184		(182)	767	23.3%	767	28.4%
Other investments	346	10.7%	(27)	18	-	337	10.2%	336	12.5%
Brait EB	323	10.0%	(52)		(7)	264	8.0%	264	9.8%
EF VII debt	(123)	(3.8%)	-		42	(81)	(2.5%)	(81)	(3.0%)
Synerlytic	169	5.2%	18			187	5.7%	187	6.9%
Echo	187	5.8%	(13)	12		186	5.7%	186	6.9%
Vertice	189	5.9%	(27)			162	4.9%	162	6.0%
Crossfin	138	4.3%	(6)	31	(20)	143	4.4%	143	5.3%
Gammatek	134	4.2%	12		(5)	141	4.4%	141	5.2%
Cash and cash equivalents	3	0.1%	(59)	-	64	8	0.2%	8	0.3%
Accounts receivable	14	0.4%	(2)		78	90	2.7%	90	3.3%
Total assets	3,226	100.0%	31	61	(30)	3,288	100.0%	2,700	100.0%
Borrowings (Drawn RCF)	(292)		-	(61)	30	(323)		(323)	
Borrowings (Black Hawk)	(168)		(8)			(176)		(176)	
Non-current liabilities	(460)		(8)	(61)	30	(499)		(499)	
Other liab. & provisions	(20)		11	-		(9)		(9)	
Current liabilities	(20)		11	-	-	(9)		(9)	
Total Liabilities	(480)		3	(61)	30	(508)		(508)	
NAV to ordinary shareholders	2,746			34		2,780		2,192	
# of shares ('mil) excl treasury	257.5			257.5		257.5		257.5	
NAV PER SHARE	10.66			0.14		10.80		8.51	

i_____i




TOTAL ASSET CONTRIBUTION

The largest 10 assets constitute 86% of total assets




PORTFOLIO COMPANY PERFORMANCE OVERVIEW


Broad based growth in both LTM revenue and EBITDA



ETHOS

LTM EBITDA GROWTH BY UNLISTED COMPANY






© Ethos | 15

PORTFOLIO COMPANY VALUATION MULTIPLES

ETHOS

Market implied EV / LTM multiples of the portfolio companies





Fund VI / VII Ai Fund Mid Market Fund - - - Implied



NAV COMPOSITION BY PORTFOLIO COMPANY

Ethos Capital's market capitalisation equals the NAV of the top 3 assets





Dec-20

Dec-21


Dec-22

financial institutions that is being leveraged to expand into adjacent products (e.g. buynow-pay-later services for SMEs)


OPTASIA TRANSACTION




During Q42022, Optasia shareholders concluded a sell-down transaction with a consortium led by an existing investor at an equity valuation that represented a **c.20% premium to the Ethos valuation**. In parallel, Optasia raised **US\$40m of debt** with proceeds used to conclude a share-buyback. Net of the R184m proceeds received, the Unrealised Value of Ethos Capital's investment in Optasia remains largely unchanged (despite the shareholding of the Ethos consortium decreasing from 20.0% to 17.4%). To date, the Optasia investment has delivered a MOIC of 3.0x (realised = 0.94x)



ETHOS





C A P I T A L	VERTICE				
% of Total Assets	6%	Ethos Capital Value: R162m -14% 6-mnth return	TMB: 1.3x vs. 1.5x in June 2022	Ethos ownership: 87% (EF VI, EAiF I & EHP)	

Vertice is a South African based **medical technology company** with a continent-wide footprint that provides **turnkey medical solutions across several healthcare sectors**.

The platform has been created through a **buyand-build strategy** with **nine successful bolt-on acquisitions** concluded since the Ethos investment



Growth Drivers

- Organic growth:

Significant potential for Vertice to grow both in terms of market share, market value and product categories within South Africa and SSA


- Integration of bolt-on acquisitions:

Vertice has concluded eight bolt-on acquisition, diversifying the product offering and increasing scale. The business is focused on integration of the acquisitions with cost savings realised as a result of consolidation into a single head-office and warehouse


- Digital Transformation:

Digital transformation of processes in the business through IoT and Ai engines, with the first Ai-driven diagnostic product successfully launched in the cardiology division. Vertice plans to introduce industry analytical engines to inform market development


Financial performance



LTM EBITDA (rebased to 100)




- While LTM Revenue increased by 10% y-o-y, EBITDA was relatively flat
- The large, specialised businesses of CVG, ONCS and Surgery are performing well and ahead of budget, while some of the mid-tier and smaller businesses have underperformed
- After a strategic review of smaller underperforming business units, a number of sub-scale businesses have been sold
- Valuation decreased by 14% over the period, resulting from a decline in maintainable earnings





Overview of other Ethos unlisted Portfolio Companies



ETHOS CAPITAL	PREMIER				
% of Total Assets	10%	Ethos Capital Value: R269m +0.4% 6-mnth return	тмв: n/a	Ethos ownership: 12.8% (EF VII, EDI & LC)	Premier 🔆

Premier is a leading South African FMCG manufacturer offering branded and private label solutions










	Six months ended	d 30 September 2022 (1H F
Revenue:	EBITDA:	EBITDA margin:
R8,672m	R821m	9.5%
+24% YoY	+16% YoY	1H FY22 = 10.1%
EBIT:	EBIT margin:	Adjusted ROIC ⁽¹⁾ :
R604m	7.0%	14.9%
+23% YoY	1H FY22 = 7.0%	1H FY22 ROIC = 12.9%
Net profit:	Net profit margin:	Net third party debt ⁽³⁾ :
R400m	4.6%	Leverage ratio of 1.4x
+119% YoY ⁽²⁾	1H FY22 = 2.6%	1H FY22 = 2.1x

Six months ended 30 September 2022 (1H FY23)

(1) Refers to return on invested capital, adjusted for capital projects not yet commissioned and revaluation of intangibles (2) Increase impacted by the equitisation of the Brait's shareholder funding instruments in May 2022, lowering interest expense (3) Includes finance leases (4) Net debt to EBITDA where 1H FY23 LTM EBITDA of R1 602m is calculated as FY22 Adjusted EBITDA of R1 490m 1H FY22 EBITDA of R709m + 1H FY23 EBITDA of R821m. 1H FY22 LTM EBITDA of R1 234m is calculated on the same basis

of 1.4x⁽⁴⁾



Virgin Active is one of the leading international health club operators providing customers with outstanding wellness and exercise experiences



MEMBERSHIP REBUILD & YIELD

Focus has been on increasing the territory membership bases. Yields expected to normalise as membership grows but an opportunity for yield enhancement exists in certain territories. Key focus on returning inner-city clubs to full capacity in UK and Australia





OPERATING COST OPTIMISATION

Restructure and management of the operating model to reduce central costs. Managing the significant inflationary impact in utility costs in UK and Italy amid the easing of high energy cost pressure and a shift to online membership enrolment will reduce sales commissions







IT PLATFORM INVESTMENT & MEMBERSHIP ENGAGEMENT

Development and roll out of the Group membership app to improve the customer experience thereby improving customer loyalty. Focus on "best of breed" membership engagement tool to reduce membership churn and provide holistic wellness offering (Padel, Virgin outdoor, health and nutrition, etc.)

CAPITAL ALLOCATION & LIQUIDITY

Focus on growth investment in the estate to expedite trajectory back to / above pre COVID levels. Quantitative, ROIC focussed decision making for new capital spend; managing the trade off between maintaining sufficient liquidity and investing capital to grow

INVEST FOR GROWTH

Continue to explore opportunities to consolidate leading positions in key markets. Investment into technology, the product and people (PTs) to enhance the membership experience, and selectively invest in new sites / enhance existing sites where growth opportunities exist

Virgin Active: key focus areas





The performance across the Group since the start of 2023 has been strong, with sales and net membership growth exceeding budget and significantly above 2019 levels. All the territories performed well, with good membership growth demonstrating Virgin Active's strong customer value proposition

Closing members: active vs freeze ('000)

956k active +17%members at 1,400 28 February 2023 1.200 1,000 Active membership 800 base equates to 89% of 2019 levels 600 400 +66k net new 200 members for the 2-0 months to February Feb-20 Apr-20 May-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Dec-20 Dec-21 Jan-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Sep-22 Jec-19 Jan-20 Mar-20 Mar-21 Jun-21 Jul-21 Sep-21 Oct-21 Feb-22 Aug-22 Nov-22 Dec-22 Jan-21 Feb-21 Apr-21 May-21 Aug-21 Nov-21 Oct-22 Jan-23 Feb-23

Freeze

Active

Virgin Active's management continues to assess options to grow the business both organically and inorganically, whilst implementing various efficiency measures across the Group



Performance review


Portfolio overview


Liquidity analysis

Outlook

ETHOS CAPITAL LIQUIDITY PROFILE

ETHOS







Performance review

Portfolio overview

Liquidity analysis

Outlook



OUTLOOK

Strong operational and financial turnaround across the portfolio

POSITIVE

Broad based recovery across the portfolio has continued despite the difficult operating conditions

Continued **market outperformance** in the NAV of the unlisted private equity portfolio

R212m of proceeds driven by asset realisations at significant premia to current valuations

Strong recent membership growth in Virgin Active demonstrates the strength of the company's positioning and recovery

Institutional interest in Premier has **revived the IPO** which will result in **significant proceeds for Brait** to repay debt

Recent announcement of **TRG merger with Ethos nearing completion,** will provide increased optionality for Ethos Capital

Board has approved the implementation of a buyback program post receipt of the Optasia proceeds

NEGATIVE

Generationally high inflationary outlook is impacting global growth prospects including emerging markets

Eskom loadshedding and policy indecision remains a key impediment to business growth

Decrease in the valuations of the listed portfolio (Brait, Brait Exchangeable and MTN Zakhele Futhi) has impacted the NAV

Exits remain difficult given the ever-changing attitude of international investment in SA

Continued share price discount to NAV will impact capital allocation decisions

ETHOS DISCLAIMER

THE INFORMATION CONTAINED HEREIN IS PROVIDED FOR INFORMATIONAL AND DISCUSSION PURPOSES ONLY AND IS NOT, AND MAY NOT BE RELIED ON IN ANY MANNER AS, LEGAL, TAX OR INVESTMENT ADVICE OR AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUL A LIMITED PARTNERSHIP INTEREST IN ANY ETHOS FUNDS. A PRIVATE OFFERING OF INTERESTS IN THE FUNDS SULL ONLY BE MADE PURSUANT TO A CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM"), THE FUND'S LIMITED PARTNERSHIP INTERESTS IN THE FUNDS SUBJECT TO THE FUNDS SUBJECT TO THE FERING MEMORANDUM"), THE FUND'S LIMITED PARTNERSHIP AGREEMENTS, WHICH MULL BE FURDISHED TO QUALIFIED INVESTMENT AND SUBSCRIPTION AGREEMENTS, WHICH MULL BE FURDISHED TO QUALIFIED INVESTMENT AND SUBSCRIPTION AGREEMENTS, WHICH MULL BE FURDISHED TO QUALIFIED INVESTMENT AND SUBSCRIPTION AGREEMENTS, WHICH MULL BE FURDISHED TO QUALIFIED INVESTMENT AND INCONDITIONS ONTAINED IN SUCH OFFERING AND WILL BE SUBJECT TO THE FERNS AND CONDITIONS CONTAINED IN SUCH OFFERING MEMORANDUM, WHICH CONDITIONS ADD THE REQUEST FOR THEIR COQUEST THAT ARE IMPORTANT TO ANY INVESTMENT DESCIDION REGARDING THE FUNDS. INTERESTS IN THE FUNDS AND ALSO CONTAINS TAX INFORMATION AND RISK DISCLOSURES THAT ARE IMPORTANT TO ANY INVESTMENT DESCIDION BE AND INVESTMENT IN THE FUNDS AND ALSO CONTAINS TAX INFORMATION AND RISK DISCLOSURES THAT ARE IMPORTANT TO ANY INVESTMENT DESCIDION EGARDING. THE FUNDS. INTERESTS IN THE FUNDS UNLED THE U.S. INVESTMENT DESCIDION ADD RISK ACT OF 1933, AS AMENDED, "QUALIFIED PURCHASERS" UNDER THE U.S. INVESTMENT COMPANY ACT OF 1940, AS AMENDED, AND "QUALIFIED INVESTMENT ADVISERS ACT OF 1940, AS AMENDED, AND "QUALIFIED INCENTION D UNDER THE U.S. INVESTMENT ADVISERS ACT OF 1940, AS AMENDED, WOULD FALL WITHIN THE CATEGORY OF "PROFESSIONAL CLIENT" AS THAT TERM IS DEFINED IN THE MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE 2014/65/EU; AND (Q) WITHIN THE CATEGORY OF "PROFESSIONAL CLIENT" AS THAT TERM IS DEFINED IN THE MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE 2014/65/EU.

WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THIS DOCUMENT DOES NOT CONSTITUTE AN INVITATION OR INDUCEMENT OF ANY SORT TO ANY PERSON IN ANY JURISDICTION IN WHICH SUCH AN INVITATION OR INDUCEMENT IS NOT PERMITTED OR WHERE WE ARE NOT QUALIFIED TO MAKE SUCH INVITATION OR INDUCEMENT. THIS DOCUMENT IS INTENDED TO BE COMMUNICATED ONLY TO SUCH PERSONS AS WE ARE LEGALLY ABLE TO SEND IT AND WHO ARE LEGALLY ABLE TO RECEIVE IT IN THEIR JURISDICTION OF RESIDENCE.

NO PERSON HAS BEEN AUTHORISED TO MAKE ANY STATEMENT CONCERNING THE FUNDS OTHER THAN AS SET FORTH IN THE OFFERING MEMORANDUM AND ANY SUCH STATEMENTS, IF MADE, MAY NOT BE RELIED UPON. THE INFORMATION CONTAINED HEREIN MUST BE KEPT STRICTLY CONFIDENTIAL AND MAY NOT BE REPRODUCED OR REDISTRIBUTED IN ANY FORMAT WITHOUT THE APPROVAL OF THE FUNDS. NOTWITHSTANDING THE FOREGOING, EACH INVESTOR AND PROSPECTIVE INVESTOR (AND EACH EMPLOYEE, REPRESENTATIVE, OR OTHER AGENT THEREOF) MAY DISCLOSE TO ANY AND ALL PROBADUL I IMITATIOD OF ANY KIND, THE TAX TREATMENT AND TAX STRUCTURE OF THE FUNDS AND ITS INVESTMENTS AND ALL MATERIALS OF ANY KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH INVESTOR RELATING TO SUCH TAX TREATMENT AND SHALL NOT INCLUDE THE NAME (OR OTHER IDENTIFYING INFORMATION NOT RELEVANT TO THE TAX STRUCTURE OR TAX TREATMENT OF ANY PERSON AND SHALL NOT INCLUDE INVESTOR RELATING TO SUCH TAX TREATMENT AND ALL PROVIDED TO ANY KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH INVESTOR RELATING TO SUCH TAX TREATMENT AND KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH INVESTOR RELATING TO SUCH TAX TREATMENT AND AND KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH INVESTOR RELATING TO SUCH TAX TREATMENT AND AND KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH INVESTOR RELATING TO SUCH TAX TREATMENT AND KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH TAX TREATMENT AND KIND (INCLUDING OPINIONS OR OTHER TAX ANALYSES) THAT ARE PROVIDED TO SUCH TAX TREATMENT AND KIND (INCLUDING THE FUNDE) OF ANY PERSON AND SHALL NOT INCLUDE INFORMATION FOR WHICH NON DISCLOSURE IS REASONABLY NECESSARY IN ORDER TO COMPLICABLES EXCURTIES LAWS.

AN INVESTMENT IN THE FUNDS WILL INVOLVE SIGNIFICANT RISKS, INCLUDING THE LOSS OF THE ENTIRE INVESTMENT, DUE TO, THE NATURE OF ITS INVESTMENTS. THE FUNDS WILL BE ILLIQUID, AS THERE IS NO SECONDARY MARKET FOR INTERESTS IN THE FUNDS AND NONE IS EXPECTED TO DEVELOP. RESTRICTIONS APPLY TO TRANSFERS AND WITHDRAWALS OF INTERESTS IN THE FUNDS, AND THE INVESTMENT PERFORMANCE OF THE FUNDS MAY BE VOLATILE. THE FEES AND EXPENSES CHARGED IN CONNECTION WITH AN INVESTMENT IN THE FUNDS MAY BE HIGHER THAN THE FEES AND EXPENSES OF OTHER INVESTMENT ALTERNATIVES AND MAY OFFSET PROFITS. BEFORE DECIDING TO INVEST IN THE FUNDS, RAVE THE FINANCE OF THE OFFERING MEMORANDUM AND PAY PARTICULAR ATTENTION TO THE INVESTMENT CONSIDERATIONS CONTAINED IN THE OFFERING MEMORANDUM. INVESTORS SHOULD READ THE OFFERING MEMORANDUM AND PAY PARTICULAR ATTENTION TO THE INVESTMENT CONSIDERATIONS CONTAINED IN THE OFFERING MEMORANDUM. INVESTORS SHOULD HAVE THE FINANCIAL ABILITY AND WILLINGNESS TO ACCEPT THE RISK CHARACTERISTICS OF THE FUNDS.

IN CONSIDERING ANY PERFORMANCE DATA CONTAINED HEREIN, YOU SHOULD BEAR IN MIND THAT PAST OR TARGETED PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS, AND THERE CAN BE NO ASSURANCE THAT THE FUNDS WILL ACHIEVE COMPARABLE RESULTS OR THAT TARGET RETURNS WILL BE MET. IN ADDITION, THERE CAN BE NO ASSURANCE THAT THE FUNDS WILL ACHIEVE COMPARABLE RESULTS OR THAT TARGET RETURNS WILL DEPEND ON, AMONG OTHER FACTORS, FUTURE OFERATING RESULTS, THE VALUE OF THE ASSETS AND MARKET CONDITIONS AT THE TIME OF DISPOSITION, ANY RELATED TRANSACTION COSTS, AND THE TIMING AND MANNER OF SALE, ALL OF WHICH MAY DIFFER FROM THE ASSUMPTIONS ON WHICH THE VALUATIONS CONTAINED HEREIN ARE BASED. THE INTERNAL RATE OF RETURNS (THE "IRRS") ARE PRESENTED ON A "GROSS" BASIS DO NOT REFLECT ANY MANAGEMENT FEES, CARRIED INTEREST, TAXES AND ALLOCABLE EXPENSES BORNE BY INVESTORS, WHICH IN THE AGGREGATE MAY BE SUBSTANTIAL. ALL IRRS PRESENTED ARE ANNUALISED AND CALCULATED ON THE BASIS OF MONTHLY INVESTMENT INFLOWS. AND OUTFLOWS. NOTHING CONTAINED HEREIN SHOULD BE DEEMED TO BE A PREDICTION OR PROJECTION OF FUTURE PREVINCE OF THE FUNDS.

PROSPECTIVE INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND EVALUATION OF THE INFORMATION CONTAINED HEREIN. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN ATTORNEY, BUSINESS ADVISER AND TAX ADVISER AS TO LEGAL, BUSINESS, TAX AND RELATED MATTERS CONCERNING THE INFORMATION CONTAINED HEREIN.

EXCEPT WHERE OTHERWISE INDICATED HEREIN, THE INFORMATION CONTAINED HEREIN IS BASED ON MATTERS AS THEY EXIST AS OF THE DATE OF PREPARATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN, WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN, WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION PROVIDED HEREIN WILL NOT BE UPDATED OR OTHERWISE REVISED TO REFLECT INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION OF THIS DOCUMENT AND NOT AS OF ANY FUTURE DATE. THE INFORMATION OF THE DATE OF THE DATE. THE INFORMATION OF THIS DOCUMENT.

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT CONSTITUTES "FORWARD-LOOKING STATEMENTS, "WHICH CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY SUCH AS "MAY," "WILL," "SHOULD," "EXPECT," "ANTICIPATE," "TARGET," "PROJECT," "ESTIMATE," "INTEND," "CONTINUE" OR "BELIEVE," OR THE NEGATIVES THEREOF OR OTHER VARIATIONS THEREON OR COMPARABLE TERMINOLOGY. DUE TO VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE SET FORTH UNDER "RISK FACTORS" AND" POTENTIAL CONFLICTS OF INTEREST" IN THE OFFERING MEMORANDUM, ACTUAL EVENTS OR RESULTS WAY DIFFER MATERIALLY FROM THOSE REFLECTED OR CONTEMPLATED IN SUCH FORWARD-LOOKING STATEMENTS. DUE TO VARIOUS RISKS AND UNCERTAINTIES, INCLUDING THOSE SET FORTH UNDER "RISK FACTORS" AND" POTENTIAL CONFLICTS OF INTEREST" IN THE OFFERING MEMORANDUM, ACTUAL EVENTS OR RESULTS OR THE ACTUAL PERFORMANCE OF THE FUND MAY DIFFER MATERIALLY FROM THOSE REFLECTED OR CONTEMPLATED IN SUCH FORWARD-LOOKING STATEMENTS. THOS, THE FUND AND ITS GENERAL PARTNER AND THEIR RESPECTIVE AFFILIATES BELIEVE THAT SUCH SOR RESULTS OR RESULTS OR RESULTS OR RESULTS OR RESULTS AND INFORMATION ARE BASED UPON REASONABLE ESTIMATES AND INFORMATION. HOWEVER, FORWARD-LOOKING STATEMENTS AND INFORMATION ARE INHERENTLY UNCERTAIN AND ACTUAL EVENTS OR RESULTS OR RESULTS CAN AND WILL DIFFER FROM THOSE PROJECTED. THEREFORE, UNDUE RELIAVES SHOULD NOT BE PLACED ON SUCH FORWARD-LOOKING STATEMENTS AND INFORMATION.

A PRIVATE OFFERING OF INTERESTS IN THE FUNDS WILL ONLY BE MADE PURSUANT TO A CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM AND THE FUNDS' SUBSCRIPTION DOCUMENTS, WHICH WILL BE FURNISHED TO QUALIFIED INVESTORS ON A CONFIDENTIAL BASIS AT THEIR REQUEST FOR THEIR CONSIDERATION IN CONNECTION WITH SUCH OFFERING. THE INTERESTS IN ANY FUTURE FUND OR INVESTMENT VEHICLE SPONSORED BY ETHOS WILL NOT BE APPROVED OR DISAPPROVED BY ANY SECURITIES REGULATORY AUTHORITY OF ANY U.S. STATE, BY THE U.S. SECURTIES AND EXCHANGE COMMINISION, OR ANY SIMILAR AUTHORITY IN ANOTHER JURISDICTION, AND ANY REPRESENTATION TO THE CONTRARY MAY BE A CRIMINAL OFFENCE.

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT IS BASED ON OR DERIVED FROM INFORMATION PROVIDED BY INDEPENDENT THIRD-PARTY SOURCES. ETHOS BELIEVES THAT SUCH INFORMATION IS ACCURATE AND THAT THE SOURCES FROM WHICH IT HAS BEEN OBTAINED ARE RELIABLE. ETHOS CANNOT GUARANTEE THE ACCURACY OF SUCH INFORMATION, HOWEVER, AND HAS NOT INDEPENDENTLY VERIFIED THE ASSUMPTIONS ON WHICH SUCH INFORMATION IS BASED.

THIS DOCUMENT IS BEING PROVIDED ON A CONFIDENTIAL BASIS. ACCORDINGLY, IT MAY NOT BE REPRODUCED IN WHOLE OR IN PART, AND MAY NOT BE DELIVERED TO ANY PERSON WITHOUT ETHOS' PRIOR WRITTEN CONSENT.